Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Intraepithelial Neoplasia 2Fractures, Bone 2Desmoid Tumors 2Triple Negative Breast Neoplasms 1Recurrence 1Precancerous Conditions 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Breast Cancer Patients in Premenopausal 1Breast Cancer Organoids 1Bone Diseases, Metabolic 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Toremifene × Clear all
NCT00003865 2017-07-13

Toremifene in Treating Patients With Ovarian Cancer

George Washington University

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡